Our prior observational studies and several other recent ones (35–38) suggest that antihypertensive medication regimens that exclusively stimulate versus inhibit AT2/AT4 receptor, driven by differences in ARB (stimulating) and ACEI (inhibiting) use, are associated with lower rates of MCI and Alzheimer’s disease (AD) and AD-related dementias (AD/ADRD). Here, AGTR2 is linked to early-onset autosomal dominant Alzheimer disease.